 | | Beheersen van bloedingsrisico’s:Wat is de balans? |
|  | | What is the balance? |
|
 | | TRITON – TIMI 38 |
|  | | Summary of ACS Treatments |
|
 | | Antiplatelet therapy: efficacy vs safety |
|  | | Thrombus composition in STEMI |
|
|
|
 | | N Engl J Med 2006;354;1464-1476 |
|
|
 | | Major Bleeding Endpoint |
|  | | Impact of MI and Major Bleeding |
|
|
|
 | | Three-Year All-Cause Mortality |
|
|
|  | | Sources and Incidence of Bleeding |
|
 | | Relative Risk of 1-Year Mortality |
|  | | Impact of Randomized Antithrombotic Therapy |
|
 | | Impact of Randomized Antithrombotic Therapy |
|  | | Time from CABG to any death |
|
 | | Bleeding from time of CABG |
|  | | Transfusions from time of CABG |
|
 | | Conclusions Bleeding in ACS |
|  | | Conclusions Bleeding in ACS |
|
 | | Risk factors for anticoagulant-related bleeding |
|  | | Higher stroke risk = higher bleeding risk |
|
 | | HAS-BLED bleeding risk score |
|  | | The HAS-BLED bleeding risk score |
|
 | | Higher bleeding rates seen with high HASBLED score |
|  | | Predictive value of contemporary bleeding risk stratification schemes |
|
 | | net clinical benefit (NCB) of VKA treatment |
|  | | Stroke Prevention in AF |
|
|
|
|
|
 | | Major Bleeding ISTH definition |
|  | | Conclusions Bleeding in AF |
|
07_F.Verheugt (PPTX 5,6MB)
Deel deze pagina met collega's en vrienden: